Biontech

Biontech Market capitalization

The The market capitalization of Biontech (BNTX) as of Nov 11, 2026 is 21.48 B EUR. In the previous year, The market capitalization was 21.48 B EUR — a change of 0.00% (lower).

Market capitalization

21.48 BEUR

YoY

0.00%

Last updated:

In 2025, Biontech's market cap stood at 21.48 B EUR, a 0.00% increase from the 21.48 B EUR market cap in the previous year.

The Biontech Market capitalization history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Market capitalization
Date
Market capitalization
Jan 1, 2018
21.48 B EUR
Jan 1, 2019
21.48 B EUR
Jan 1, 2020
21.48 B EUR
Jan 1, 2021
21.48 B EUR
Jan 1, 2022
21.48 B EUR
Jan 1, 2023
21.48 B EUR
Jan 1, 2024
21.48 B EUR
Jan 1, 2025
21.48 B EUR
The Biontech Market capitalization history
YEARMarket capitalizationYoY
21.48 BEUR0.00%
21.48 BEUR0.00%
21.48 BEUR0.00%
21.48 BEUR0.00%
21.48 BEUR0.00%
21.48 BEUR0.00%
21.48 BEUR0.00%
21.48 BEUR0.00%
21.48 BEUR—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Biontech Stock analysis

What does Biontech do? BioNTech SE is a German biotech company specializing in the development of innovative therapies for cancer and other serious diseases. The company was founded in 2008 by Ugur Sahin and Özlem Türeci and is headquartered in Mainz. History: BioNTech was established to develop novel treatment options for cancer patients. Originally started as a pure research company, the company has since evolved into a global leader in mRNA-based therapeutics. In recent years, BioNTech has entered into numerous collaborations and partnerships with renowned pharmaceutical companies and other research institutions to strengthen its innovative power and competitiveness. Business model: BioNTech's business model involves developing novel mRNA-based therapeutics for the treatment of cancer and other serious diseases. The company relies on close collaboration with other research institutions and pharmaceutical companies to leverage the latest scientific knowledge and technologies. BioNTech aims to bring its therapeutics to market as quickly as possible to enable more effective treatment for patients worldwide. Divisions: BioNTech is divided into various divisions to optimize its research activities. One of the most important divisions is cancer research, in which the company specifically seeks new treatment options for various types of cancer. BioNTech focuses on the development of personalized cancer immunotherapy tailored to the individual needs of each patient. In this context, the company works closely with other researchers and oncologists to achieve the best possible outcomes. Another important area of BioNTech is vaccine development. The company uses mRNA technology to rapidly and effectively develop vaccines against various infectious diseases. In 2020, BioNTech, together with the US pharmaceutical company Pfizer, brought the first mRNA vaccine against COVID-19 to the market, which has high efficacy and safety. This technology enables rapid response to new pathogens and targeted vaccine development. Products: BioNTech offers a variety of therapeutics and vaccines based on mRNA technology. One of the company's most important products is the mRNA vaccine against COVID-19, which is in use worldwide. In addition, BioNTech develops personalized cancer immunotherapies tailored to the individual characteristics of patients' tumors. Another product of BioNTech is mRNA immunotherapies that can be used for various autoimmune diseases. Conclusion: BioNTech is an innovative biotech company specializing in the development of mRNA-based therapeutics for the treatment of cancer and other serious diseases. With its business model that relies on collaborations and partnerships, the company is able to rapidly and effectively respond to new challenges while staying scientifically up to date. BioNTech has brought a variety of products to the market in a short period of time that have high efficacy and safety, thereby helping patients worldwide. Answer: BioNTech is a German biotech company that specializes in the development of mRNA-based therapeutics for the treatment of cancer and other serious diseases. Biontech is one of the most popular companies on Eulerpool.

Market capitalization Details

Exploring Biontech's Market Capitalization

Biontech's market capitalization represents the total dollar market value of the company’s outstanding shares of stock. It is calculated by multiplying the company's shares outstanding by the current market price of one share. This metric is a vital indicator of a company’s size, strength, and overall market value.

Year-to-Year Comparison

A yearly comparison of Biontech's market capitalization provides investors and analysts insights into its growth and valuation trends. An increase signifies market confidence and business expansion, while a decrease may point towards declining market value or business contractions.

Impact on Investments

Biontech's market capitalization plays a pivotal role in investment decisions. It aids investors in assessing the company's risk and return profiles. Larger companies are often considered more stable but may offer lower growth potential, while smaller companies might offer significant growth prospects but come with higher risk.

Interpreting Market Capitalization Fluctuations

Variations in Biontech’s market capitalization can be attributed to several factors, including changes in stock price, outstanding shares, and market sentiment. Understanding these fluctuations helps investors evaluate the company's current standing and future potential in the competitive landscape.

Frequently Asked Questions about Biontech stock

The market capitalization of Biontech is 21.48 B EUR in 2025.

The market capitalization of Biontech changed from 21.48 B EUR to 21.48 B EUR, representing a 0.00% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of The market capitalization Biontech since 2006 – with annual values, charts, and detailed analysis.

Market capitalization (German: Market capitalization, English: market capitalisation or market cap) is the calculated total value of all shares of a publicly traded company. The market capitalization of a company reflects the current market consensus on the value of the equity of a publicly traded company. It is determined by the supply and demand for the company's shares. Thus, market capitalization is significantly influenced by expectations in the stock market regarding the future earnings power of the company and, therefore, can be subject to significant fluctuations.

Number of shares * share price = market capitalization

To evaluate The market capitalization's EUR, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for The market capitalization.

A 'good' EUR varies by industry and company stage. On Eulerpool, you can compare The market capitalization's Biontech with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Biontech

All Key Metrics — Biontech